
Ncardiarevenue & acquisition
United States
Ncardia was acquired.
Ncardia is a biotechnology company specializing in the development and manufacture of induced pluripotent stem cell (iPSC)-derived cell models and assays for drug discovery, safety, and efficacy testing.
Ncardia revenue
Ncardia has not published its revenue. Growjo puts it at about $8M a year (December 2023).
| As of | Revenue | Source |
|---|---|---|
| Dec 2023 | $8MEST | Growjo estimate |
Who owns Ncardia
Another company owns Ncardia. The date and price of the deal are not on record.
Ncardia CEO, founders & employees
Herman Spolders founded Ncardia and led it as CEO. Ncardia had 46 employees (December 2023, Growjo estimate).
- Herman SpoldersFounder & CEO
Ncardia FAQ
What was Ncardia's revenue?
Growjo estimates Ncardia's revenue at about $8M a year (December 2023). The company hasn't published its own figure.
How many employees does Ncardia have?
Growjo estimates Ncardia's headcount at about 46 (December 2023).
Who founded Ncardia?
Herman Spolders founded Ncardia.
Categories
How this page is sourced
2 estimates. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Oct 5, 2026Data disclaimerReport a correctionClaim this profileRun Ncardia? Join the podcast